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Abstract  
CD39 and CD73 are surface-expressed ectonucleotidases that hydrolyze ATP in a 
highly regulated, serial manner into ADP, AMP and adenosine. The end-product, 
adenosine, has both tumor-promoting and immunosuppressive effects. The aim 
of this study was to determine CD73 expression on immune cells in pleural 
effusion (PE) in order to have a better understanding of the immune 
environment in mesothelioma. PE- or blood-derived CD14+ cells of 
mesothelioma patients and healthy donors were analyzed by flow cytometry for 
the expression of CD39 and CD73. CD73-induction was studied by exposure of 
CD14+ cells to the soluble fraction of PE (sPE), while the signaling mechanism, 
responsible for CD73 induction, by phosphoflow cytometry and receptor-
inhibition studies. We observed CD73 expression on CD14+ cells in PE but not 
peripheral blood of mesothelioma patients or healthy donors. CD73 expression 
was inducible on CD14+ cells with sPE, cyclic-AMP (cAMP)-inducers (forskolin 
and prostaglandin-E2 (PGE2)) and adenosine. Inhibition of PGE2 receptors or 
adenosine A2 receptors blocked CD73-induction by sPE. sPE treatment triggered 
protein kinase A and p38 activation. However, signal-transducer and activator of 
transcription 3 (STAT3)-blocking led to enhanced CD73 expression, 
demonstrating a hitherto unknown negative control of purinergic signaling by 
STAT3 in CD14+ cells. TNFα production by CD73+ CD14+ cells was significantly 
impaired in the presence of AMP, confirming immunosuppressive function. 
Taken together, CD73 expression can be induced by PGE2, cAMP or adenosine on 
human CD14+ cells. We suggest that targeting this autocrine loop is a valid 
therapeutic approach in mesothelioma that may also enhance immunotherapy.       
(Words: 247)  
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Introduction 
 Solid tumors have much higher levels of extracellular ATP and adenosine 
than normal tissues. 1 ATP represents a danger signal via binding to P2 
purinoreceptors, such as P2X7 on leukocytes, contributing to inflammation. This 
signaling has been reported to have tumor suppressor effects, and, interestingly, 
P2X7 levels are lower in cancer than in normal tissues. 2 Conversely, the ATP-
metabolite adenosine has extensive immunosuppressive effects 3, 4 via binding to 
a range of adenosine-receptors present on most immune cells. 5 ATP conversion 
into ADP and 5’-AMP is catalyzed by CD39, while AMP is hydrolyzed by CD73 to 
adenosine. In the tumor microenvironment, the CD39/CD73/adenosine axis 
contributes not only to immunosuppression but also directly supports tumor 
growth, differentiation, metastasis and angiogenesis. 2, 6, 7. 
Cell surface co-expression of CD39 and CD73 ensures rapid ATP uptake from the 
pericellular environment leading to topical generation of adenosine. 1 Double 
positive cells or extracellular vesicles, such as exosomes 8, can act as efficient 
enzyme-delivery systems reaching distant sites. The co-expression of these 
enzymes on immune cells has been demonstrated for activated mouse Treg and 
Th17 cells 9, 10 but untreated human Tregs in the circulation only express low 
levels of intracellular CD73. 11 Mouse peritoneal macrophages may also co-
express these enzymes, 12 while healthy non-activated human blood monocytes 
and macrophages have abundant expression of CD39 but not CD73 on the cell 
surface. 13, 14   
Ectonucleotidase expression can be controlled by the microenvironment; e.g. 
CD39 expression is regulated by IL-27 in ovarian cancer, 15 while CD73 is 
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upregulated by hypoxia on epithelial cells 16, by TGFβ on murine leukocytes 17 
and by signal-transducer and activator of transcription-3 (STAT3) activation on 
murine Th17 cells. 10 Endothelial cells were observed to respond to increased 
intracellular cAMP levels via an adenosine-mediated paracrine pathway leading 
to CD73 upregulation. 18  
The aim of this study was to reveal whether immune cells in the pleural effusion 
(PE) of MPM express CD73.  
Malignancy-associated PE is a relatively easily accessible material in MPM. It is a 
complex milieu that reflects some of the characteristics of the tumor and 
represents a rich source of tumor and immune cells and soluble factors. PE is 
responsible for indirectly influencing tumor cells, regulating inflammation and 
contributing to tumor dissemination. 19 The population of CD14+ cells in the 
tumor microenvironment consists of tumor-associated macrophages and 
monocytes.  In mesothelioma, M2 macrophages with immunosuppressive 
features have been observed in the tumor; their ratio (CD163/CD68) having a 
negative prognostic value. 20 The effect of sPE on skewing macrophage 
differentiation into M2 type has recently been demonstrated, 21, 22 however, 
CD73 expression has not been studied on these cells.  
We report here the presence of CD39/CD73 co-expressing CD14+ cells in the PE 
of patients with MPM. When healthy donor peripheral blood mononuclear cells 
(PBMC) were exposed to the cell-free, soluble fraction of PE (sPE), surface 
expression of CD73 was induced in a dose- and cell type-dependent manner on 
CD14+ but not on CD3+ cells. The effect of sPE on CD73 induction was mimicked 
by cAMP-inducing agents, such as forskolin or PGE2, or with adenosine, in a 
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protein kinase A (PKA)- and p38-dependent manner. Conversely, sPE-induced 
CD73 expression was significantly amplified by inhibiting STAT3 
phosphorylation. We demonstrate that CD73, induced on CD14+ cells, is 
functional, as its activity suppresses TNFα production. These observations point 
towards a cross-talk between cAMP/adenosine and STAT3 signaling in the 
regulation of CD73 expression on monocytes in the tumor microenvironment, 
offering novel treatment targets in MPM.  
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Results 
CD73 is expressed on CD14+ cells in mesothelioma-associated PE. The aim 
of our study was to explore whether tumor-associated immune cells co-express 
CD39 and CD73. The cellular fraction of PE from MPM patients was phenotyped 
and the frequencies of those CD14+ or CD3+ cells that co-expressed CD39 and 
CD73 were determined and compared with frequencies found in patients’ or 
healthy donors’ PBMC. We found CD73 expression on CD14+ cells in PE but not in 
blood (Fig. 1A upper panel). The mean frequency of CD39+CD73+ double positive 
CD14+ cells was 17.4% in the PE of three donors (Fig. 1B) compared to <0.5% in 
PBMC (Figure 1B). CD39 was expressed at comparable levels on CD14+ cells in 
healthy or patient PBMC (mfi: 455 and 547), while in PE its expression was more 
than three-fold higher (mfi: 1,732)  (Fig. 1A upper panel). CD73 expression levels 
and co-expression with CD39 were also analyzed on CD3+ cells: The frequency of 
CD3+ cells expressing CD73 was not elevated in PE compared to that in PBMC 
(Fig. 1A, lower panel). These results demonstrate a specific induction of CD73 in 
the tumor environment on myeloid (CD14+) but not T (CD3+) cells. 
 Only CD14+ cells in PE co-express CD73 and CD39.  Tumor cells have 
been shown to express CD73 while some also co-express CD39. 23 In order to 
demonstrate that the CD39+CD73+CD14+ cells in PE are distinct from e.g. tumor 
or mesothelial cells, which are CD14-, CD73 expression on CD3-CD14-/FSChigh 
cells(T) vs. CD3-CD14+FSCintermediate (M) cells was studied (Fig. 1C). As expected, 
the CD14- FSChigh (T; potentially tumor-containing) cell population was only 
present in the PE and not blood. These cells expressed CD73 but not CD39 and 
this pattern was similar to that we observed on established primary 
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mesothelioma cell lines 24, 25 (Fig. 1D). These results prove that CD39+CD73+ co-
expression is a characteristic of CD14+ monocytes/macrophages in MPM-
associated PE.      
 CD73 expression is induced selectively on CD14+ cells by sPE. In 
order to determine whether soluble factors in PE are responsible for inducing 
CD73 expression on CD14+ cells, healthy donor PBMC was exposed to increasing 
concentrations of sPE for 48h in vitro. Flow cytometry analysis of CD14+ cells 
demonstrated that CD73 is significantly upregulated by sPE, pooled from four 
patients, and this upregulation is dose-dependent (Fig. 2A, upper panel). CD73 
induction was the property of 9/9 sPEs studied. While four sPE samples were 
pooled for the experiments carried out in this paper (individual effects shown in 
Fig S1 and patient details in Table 1) an additional five sPE samples (individual 
or pooled) have confirmed the findings (Supplementary Figure 1). One sample 
(sPE9) derived from a patient with sarcomatoid mesothelioma. The induction of 
CD73 expression was protein-specific, as CD39 expression levels were not 
altered. It was also cell type specific, as CD39+CD73+ cell frequencies remained 
unchanged in the CD3+ subset (Fig. 2A, lower panel). Phenotyping of sPE-treated 
CD14+ cells indicated CD14, CD16 and CD163 upregulation, compared to that on 
untreated cells, while CD62L, CD86 and HLA-DR were expressed at lower levels 
following sPE-treatment (See Supplementary Fig. 2.A). We also tested for PDL-1 
antigen expression, a marker of immunosuppression, but its level was not 
enhanced by treatment with sPE, in fact it was downregulated. HLA-DR, CD16 
and CD163 expression were lower on CD73+ cells than on CD73-cells in the sPE-
treated group (See Fig. S2.B).  The results indicate that soluble factors in PE have 
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a significant and selective effect on inducing CD73 expression on CD14+ cells, 
however, CD73+CD14+ cells do not express typical M2 macrophage markers. 
 PGE2 induces CD73 expression on CD14+ cells. As CD73 was only 
expressed on MPM patients’ CD14+ cells in the PE but not in blood, we analyzed 
the differences in cytokine composition of PE vs. plasma. A cytokine array 
revealed that sPE contained elevated levels of IL-6, IL-8, IL-13, IP-10 and MCP-1 
(Fig. S3) compared to plasma, while ELISA experiments demonstrated that 
hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and 
stromal cell-derived factor-1 (SDF-1) levels were also higher in sPE than in 
plasma (Fig. 2B). Next we tested the concentration of PGE2 in the pooled sPE 
used in the experiments: PGE2 concentration was more than two-fold higher in 
the sPE than in MPM plasma (Fig. 2B last panel). On the other hand, we did not 
find elevated TGFβ levels in PE compared to that in plasma by TGFβ ELISA (Fig 
2B). We then screened a variety of cytokines for their ability to induce CD73-
expression on monocytes. We found that IL-6, IL-8, HGF, VEGF and SDF, alone or 
in combination (Fig 2C), or TGFβ alone (not shown) or in combination with IL-6 
and IL-10 failed to induce CD73 expression (Fig. 2D).  However, when CD14+ 
cells were treated with 100 ng/ml PGE2 for 48h, significant induction of CD73 
expression was observed (Fig. 2E).  In order to demonstrate that PGE2 in sPE is a 
relevant factor that can drive CD73 induction, G-protein coupled E-type 
prostanoid receptors, EP2 and EP4, that have been demonstrated to be the main 
PGE2 receptors present on human monocytic cells 26, were blocked before 
exposing CD14+ cells to sPE. The near complete inhibition of CD73 expression 
(Fig 2E) confirmed that PGE2 in sPE plays a dominant role in the induction of 
CD73 on human CD14+ cells. PGE2 is a known inducer of intracellular cAMP. 27 
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Thus, next we tested if cAMP is involved in CD73 induction, by stimulation with 
forskolin, which is a receptor-independent, pharmacological inducer of 
intracellular cAMP. Indeed, forskolin proved efficient in inducing CD73 
expression on healthy donor CD14+ cells (Fig. 2F), confirming the role of cAMP 
signaling in CD73 upregulation. 
 Adenosine can also induce CD73 expression on CD14+ cells. 
Extracellular adenosine is a relevant factor in supporting mesothelioma, as we 
show it in a tumor cell growth support experiment, where NECA significantly 
enhanced primary mesothelioma cell line proliferation (Fig. S4). As adenosine, 
signaling via the A2A receptor, has also been shown to induce intracellular 
cAMP28, we tested the effect of the adenosine analogue NECA on CD73 
expression. We found significant CD73 induction on CD14+ cells by NECA (Fig. 
3A). To confirm the relevance of this observation in our PE study, we blocked A2A 
adenosine receptor before CD14+ cells were exposed to sPE. A partial, but 
significant prevention of CD73 induction was observed both at 24h and 48h (Fig. 
3B). The results show that the adenosine pathway triggers the induction of CD73 
surface expression on CD14+ cells, generating a potentially self-amplifying 
autocrine loop.  
 CD73 is induced on CD14+ cells by sPE via PKA and p38 signaling. As 
cAMP is known to signal via PKA and p38, we tested whether exposure of CD14+ 
cells to sPE activates this pathway. First we pre-treated the cells with the PKA 
inhibitor H-89. Upon sPE- or PGE2-treatment, CD73 upregulation was 
significantly inhibited (Fig. 3C) by the PKA inhibitor. The phosphorylation of p38 
after exposure of monocytes to sPE was also tested. p38 activation was elevated 
as early as 10 min, compared to untreated cells, and gradually decreased by 4h 
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(Fig. 3D). Anisomycin (antibiotic, known to activate p38), used as a positive 
control, displayed slightly slower kinetics of p38 phosphorylation (Fig. 3D). 
Inhibition of p38 phosphorylation with the small molecule inhibitor SB203580 
was also carried out, and it completely abolished CD73 upregulation either by 
sPE or NECA (Fig. 3E). These results demonstrate that CD73 expression can be 
induced on CD14+ cells by PGE2 and adenosine, soluble factors relevant in 
cancer, and this induction can be mimicked by forskolin via the cAMP/PKA/p38-
signaling pathway.  
 CD73 induction on CD14+ cells by sPE is enhanced by STAT3 
inhibition. In mouse Treg cells, STAT3 activation contributed to the 
upregulation of CD73. 10 In order to explore the role of this pathway in the 
induction of CD73 expression on human monocytes, we tested if sPE-treatment 
triggers STAT3 phosphorylation. Exposure of CD14+ cells to sPE indeed resulted 
in significant STAT3 phosphorylation at 30 min, with sustained kinetics, as it was 
still significantly elevated at 2h and 4h compared to that in untreated cells (Fig. 
4A). In order to explore the consequences of STAT3 activation, we inhibited 
STAT3 phosphorylation with the small molecule inhibitor Cpd188 in cells 
exposed to sPE, at a concentration we have established previously. 29 
Unexpectedly, in the presence of the inhibitor, sPE-mediated induction of CD73 
expression became significantly enhanced (Fig. 4B). sPE did not activate STAT1 
and Cpd188 had no off-target effects on this transcription factor (Fig 4C, left 
panel). These results indicate that STAT3 exerts a negative effect on CD73 
induction and thus it may have the ability to curb excessive adenosine 
production. This was confirmed by an experiment where IL-6 was added 
together with sPE or NECA to CD14+ cells. In combination with sPE, IL-6 had no 
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effect on CD73 induction (Figure 4D), presumably because IL-6 was already 
present at elevated levels in the sPE (as shown on Fig S3). However, when added 
with NECA, CD73 induction was significantly inhibited by IL-6. The negative 
regulation of adenosinergic signaling in human monocytes/macrophages by 
STAT3 represents a novel (i.e. a non-immunosuppressive) role for STAT3 in the 
immune regulation of cancer.  
 sPE-induced CD73 on CD14+ cells is functional. Finally, we determined 
if CD73, upregulated by sPE on CD14+ cells, is able to impair the function of these 
cells. Highly purified, healthy peripheral blood CD14+ cells were treated with sPE 
overnight. Adenosine A2A and A2B receptor-inhibitors were added to the cells, 
followed by AMP and LPS. TNFα production was assessed by intracellular 
cytokine staining (Fig. 4E). Adding AMP to these cells resulted in a nearly 50% 
inhibition of LPS-induced TNFα production. In the presence of adenosine 
receptor inhibitors, AMP’s negative effect on cytokine production was prevented, 
proving that the inhibition is adenosine-mediated. Adenosine receptor 
inhibitors, added to CD14+ cells in the presence of LPS but without AMP, resulted 
in a small but significant increase in TNFα production, presumably due to a low 
level of adenosine being intrinsically present in the cultures. These experiments 
provide evidence that CD73, induced by sPE, partakes in the generation of local 
immunosuppression in mesothelioma in an adenosine receptor-mediated 
manner.  The suggested mechanism of positive and negative regulation of CD73 
expression is summarized on Fig. 5.  
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Discussion 
This study shows that mesothelioma-associated PE has a regulatory role in the 
purinergic pathway by inducing the expression of CD73 on myeloid cells. CD73 is 
a rate-limiting enzyme in the hydrolysis of ATP to adenosine. We demonstrate its 
induction on CD14+ cells by sPE in a PGE2- or adenosine-dependent manner, via 
cAMP, PKA and p38 signaling.  As a functional consequence, pro-inflammatory 
cytokine production is impaired by CD73-expressing CD14+ cells in the presence 
of AMP; this impairment is reversible by A2 receptor-inhibitors.  
 Human monocytes and macrophages are largely CD73 negative but 
express CD39. 13 Although CD73 upregulation has been reported on other cell 
types, such as on T cells, epithelial cells 30, endothelial cells 18 and murine 
leukocytes, 17  such an observation has only recently been made on human 
macrophages in ovarian cancer. 31 We have reported earlier that tumor cells may 
be present in mesothelioma PE 24 and here we demonstrate that these tumor 
cells in PE may express CD73 but not CD39. Co-expression of CD73 and CD39, 
which is only observed on CD14+ cells in PE but not in blood, makes these tumor-
associated macrophages (TAM) a key cell type in purinergic regulation. 
CD39/CD73 double positive TAM have the potential of reducing extracellular 
ATP levels by hydrolysis, leading to the generation of adenosine, which then 
helps in maintaining a tumor-supporting and immunosuppressive 
microenvironment. We observed that sPE skews monocytic differentiation 
towards M2-like macrophages, as detected via CD14 and CD163 upregulation 
and downregulation of HLA-DR. This confirms recent findings on the effect of 
MPM-PE on macrophages21, 22. However, CD14+ cells, which are also positive for 
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CD73, are phenotypically distinct from M2-like cells as their CD163 expression 
level is significantly lower than that on CD73- cells and there are no differences 
in CD14 expression levels. Thus we conclude that CD73 induction is distinct from 
CD14+ cell differentiation towards M2-like macrophages. PDL-1 expression was 
also downregulated or remained low on these cells, which may not be surprising 
as PDL-1 induction is the consequence of type I and II interferon stimulation 32, 
while in the tumor milieu, myeloid cells predominantly encounter anti-
inflammatory factors. 
 Extracellular adenosine is elevated in numerous cancer tissues 1 with 
direct tumor-promoting effects, and indirect, immunosuppressive functions, by 
inhibiting effector T cells or promoting regulatory T cell activity. 6, 33 In 
mesothelioma, high concentration of extracellular adenosine (3 mM) has been 
reported to cause apoptosis of tumor cells. 34 However, we show here that 
physiological concentrations support tumor growth, indicating the relevance of 
adenosine in the progression of this disease.  
 We demonstrate in this study that PGE2 induces the expression of CD73 
on monocytes. PGE2 is the main product of COX2  and COX2-overexpression is a 
negative prognostic factor in MPM. 35 PGE2 has recently been identified at 
elevated concentrations in MPM-PE. 22 It has been suggested that PGE2 is a 
potential factor to induce immunosuppressive M2 macrophages, however, 
mechanistic data have been lacking to support this. PGE2 has been shown to 
increase cAMP levels via prostanoid receptors EP2/EP4. We demonstrate here 
that CD73 upregulation on CD14+ cells by sPE is blocked by inhibiting its 
receptors, EP2 and EP4, confirming the role of PGE2 in the regulation of the 
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adenosinergic pathway in mesothelioma. PGE2 has also been shown to impair 
purinergic signaling by ATP in macrophages 36, which suggests that in the 
presence of PGE2, extracellular ATP is preferentially undergoing hydrolysis by 
myeloid cells.  
 cAMP signals via PKA and p38, and this signaling has been shown to 
suppress the production of TNFα and IFNγin keratinocytes. 37 We demonstrate 
here that sPE activation of the cAMP-PKA-p38 pathway leads to CD73 induction 
on the surface of human CD14+ cells, as small molecule inhibitors of PKA and p38 
prevent CD73 induction. As CD73 enzyme activity results in the generation of 
adenosine, which induces further CD73 expression on myeloid cells, we describe 
a self-amplifying loop here which may be similar to the immunosuppressive 
autocrine adenosinergic loop described for Treg cells. 9 
 When testing STAT3 activation in CD14+ cells exposed to sPE, we found 
simultaneous phosphorylation of p38 and STAT3. STAT3 can be activated by IL-
6, IL-10 or VEGF; adenosine can mediate STAT3 activation via IL-10, as 
demonstrated in mouse macrophages 38, while PGE2 itself has also been shown to 
phosphorylate STAT3 in cardiomyocytes. 39  Signaling via STAT3 can upregulate 
CD73 in Th17 cells. 10 However, when STAT3 was blocked in our model, instead 
of inhibition of CD73 upregulation, we observed significantly enhanced CD73 
expression. There is no known inhibitory influence of STAT3 on cAMP signaling; 
however, a possible explanation is that there may be a competition for CREB 
binding protein (CBP) between cAMP-activated CREB and STAT3. Thus, 
inhibition of STAT3 may favor CREB binding, similar to what has been shown in 
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the human myeloid THP cell line. 40 We are currently investigating this 
regulatory effect of STAT3 on CD73 expression.  
 Taken together, we demonstrate here that PGE2 in mesothelioma-
associated PE regulates CD73 expression on CD14+ cells in a cAMP-mediated 
manner, while STAT3 acts as a negative regulator of this process. A2A-receptor 
inhibition has been shown to synergize with the effect of PDL-1 immune 
checkpoint inhibitors in preclinical tumor models 41. This treatment combination 
is currently undergoing clinical trials in numerous advanced solid tumors 
(ClinicalTrials.gov: NCT02655822; Corvus Pharmaceuticals; Novartis NIR 178). 
Humanized CD73 blocking antibodies are also under development or in clinical 
trials, following promising results in combination with checkpoint inhibitors in 
pre-clinical models. 42 (Innate Pharma Inc.: AACR 2016 Poster #2344; 
MedImmune, MEDI9447: Phase I in combination with anti-PDL1; Bristol Myers 
Squibb: in the pipeline). Our findings provide new mechanistic information 
about potential beneficial effects of targeting CD73 or the A2A-receptor in 
mesothelioma.  
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Materials and Methods 
 Blood, PE and cell lines. Ethical approval for the study was granted by 
the South-East Wales Research Ethics Committee. Venous blood was collected 
from healthy donors or MPM patients. PE samples were collected into sterile 
containers attached to indwelling catheters. Patient characteristics are described 
in Table 1. sPE stock was prepared from four donors and used throughout these 
experiments. The sPE fraction was prepared by depleting cells (centrifugation at 
2,000 rpm for 20min), filtering the supernatant (0.22μm) and storing aliquots at 
-80oC. Human peripheral blood mononuclear cells (PBMC) from healthy donors 
were separated by Histopaque density gradient centrifugation. CD14+ cells were 
enriched by magnetic separation (19058; StemCell Technologies), according to 
the manufacturer’s instructions. Primary mesothelioma cell lines were 
developed as described before. 24 Met5A mesothelial cells were purchased from 
the ATCC (Manassas, VA).  
 Reagents. Human recombinant IL-6 (200-06), IL-8 (200-08), IL-10 (200-
10), VEGF (100-20A), HGF (100-39), TGFβ (100-39C) and SDF-1 (300-28A) were 
purchased from Peprotech. NECA (1691), PGE2 (2296), Forskolin (1099), 
SB203580 (1202; p38-inhibitor); H-89 (2910; PKA-inhibitor); SCH58261 (2270; 
adenosine A2A receptor-inhibitor) and PSB0788 (3199; adenosine A2B receptor-
inhibitor) were obtained from Tocris. Cpd188 (573125; STAT3-inhibitor) was 
obtained from Calbiochem and Anisomycin (A9789) from Sigma. AH-6809 and 
AH-23848 (EP2 and EP4 PGE2-receptor inhibitors) were obtained from Cayman 
Chemicals (CAY-14050 and CAY-19023). The inhibitor concentrations and 
treatment details are described in the figure legends. Antibodies against CD14 
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(25-0149 or 11-0149), CD3 (47-0036), CD39 (17-0399), TNFα-
and pSTAT1 (12-9008-42) were purchased from Affymetrix and those 
for CD73 (550257), phosphorylated p38-MAPK (612565) and STAT3 
phosphorylation sites pY705 and pS727 (612569 and 558557 respectively) were 
obtained from BD Biosciences.  
 sPE treatment and flow cytometry. CD14+ cells at 5x105/500μl were 
treated with 12.5% sPE for 48h unless otherwise stated. Cell surface labeling 
was carried out on ice for 30 min using antibodies specific for CD14, CD3, CD39 
and CD73. For phosphoprotein detection, cells were first fixed as above, 
permeabilized (ice-cold 80% methanol for 30 min), then labeled with 
PhosphoFlow antibodies for p38-MAPK, pSTAT3 (pY705/pS727 antibodies 
applied together), pSTAT1 or relevant isotype controls. Staining for CD14 and 
CD3 was then carried out for 45 min at room temperature. FACSCanto or 
FACSVerse cytometers (BD-Biosciences) were used for acquisition and FACSDiva 
software for data analysis. 
 ELISA. PGE2 (KGE004B), HGF (DHG00), VEGF (DVE00), TGFβ (DY240-05) 
and SDF-1 (DSA00) levels from sPE samples or MPM and healthy plasma samples 
were determined by ELISA (R&D Systems), according to the manufacturer’s 
instructions. 
 TNFα release by sPE-treated CD14+ cells. CD14+ cells were isolated 
from healthy PBMC (StemCell Technologies) with 94% purity. 2.5x106 cells were 
incubated in 2ml media overnight in the presence or absence of 12.5% sPE. 
Adenosine A2A and A2B receptor-inhibitors (200 nM each) were added to cells for 
30min followed by 200 μM AMP (01930, Sigma) for 30 min, and 200 ng/ml 
lipopolysaccharide (LPS; L4391 Sigma) for 1h. Intracellular cytokine staining 
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was carried out as described 43 following 4h incubation with Golgi Plug (55509) 
and Golgi Stop (554724, both BD-Biosciences). Fixed (00-82249) and 
permeabilized (00-8333-56, both Affymetix) cells were labeled with CD14 and 
TNFα antibodies at room temperature for 30 min. Flow cytometry was carried 
out as above.    
 Statistical analysis. Results are presented as means+SD of triplicate 
measurements unless it is stated otherwise. Statistically significant differences 
were determined using Student’s t-test or ANOVA with Tukey post hoc test 
(GraphPad Instat 3.06). A p-value of <0.05 was considered statistically 
significant. 
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Figure Legends 
Figure 1. CD73 is expressed on tumor-associated CD14+ cells. (A) CD73 (y-
axis) and CD39 (x-axis) fluorescent intensity are shown on CD14+ (upper panel) 
or CD3+ cells (lower panel) from PE, or patient (PBMC-MPM) and healthy donor 
PBMC (PBMC-HD). The first dot plot shows CD3 and CD14 gating, while in the 
second column CD39 isotype labeling is shown. The numbers represent % 
double positive cells in the first row and single+double positive cells in the 
second row. (B) Summary of results, as in (A), from multiple donors. Means+SD 
of results are shown, *p<0.05, **p<0.01. (C) Upper panel: gating on 
CD14lowFSChigh cells (T) and on CD14high FSCintermediate cells (M) in PE, MPM and 
healthy donor PBMC. Lower panel: CD73 and CD39 expression on gated cells. (D) 
CD73 and CD39 expression on primary mesothelioma cell lines and non-
malignant Met5A mesothelial cells.  
Figure 2. sPE, PGE2 and forskolin induce CD73 expression on CD14+ cells. 
(A) CD73 induction on CD14+ cells (upper panel) or on CD3+ cells (lower panel) 
of healthy donor PBMC, 48h after treatment with increasing doses of sPE. The 
first panel shows staining with control isotype antibodies.  The numbers 
represent % of CD14+ or CD3+ cells, co-expressing CD73 and CD39. A 
representative of 12 experiments is shown. (B) ELISA measurements of growth 
factors, from PE or plasma, are shown as indicated (n=3-6). The boxes (panels 1-
4) represent the 25th and 75th percentile values, the lines represent the means. 
The last panel shows the mean and SD of PGE2 concentrations from four MPM 
plasma donors and the sPE mix, which has been described earlier.  (C) CD73 
expression on healthy donor CD14+ cells following treatment with 10ng/ml IL-6, 
  20
10ng/ml IL-8, 50ng/ml HGF, 50ng/ml VEGF, 10ng/ml SDF-1 or the mix of these 
factors (Mix) or sPE at 50%, or (D) with 12.5% PE or a mix of 10ng/ml TGFβ, 10 
ng/ml IL-6 and 2 ng/ml IL-10, as indicated. (E) Treatment of healthy donor 
CD14+ cells with 12.5% sPE or 100nM PGE2 in the presence or absence of PGE2-
receptor inhibitors (PGE2i) AH-6809 and AH-23848 (5μM each). (F) 250μM 
forskolin treatment of healthy donor CD14+ cells. C-F: Means+SD of CD73 mfi 
values from triplicate cultures are shown. C: FACS Canto, D-F: FACS Verse flow 
cytometer. *p<0.05, **p<0.01, ***p<0.001. 
Figure 3. CD73 expression is also induced by adenosine; PKA- and p38-
dependent pathway. (A) CD73 induction by NECA (100nM) and sPE or (B) with 
sPE at 4, 24 and 48h in the presence or absence of adenosine A2A receptor 
inhibitor (SCH58261, 200nM). (C) CD73 expression on sPE- or PGE2 (250μM)-
treated CD14+ cells in the presence or absence of a PKA inhibitor (PKAi) H-89 
(10μM). (D) p38 phosphorylation by sPE in CD14+ cells. Means+SD of 
phosphorylated p38 mfi from triplicate samples for sPE treated cells are shown 
while positive control anisomycin (35μM) and untreated control are represented 
by single samples. (E) CD73 expression on sPE- or NECA (250nM)-treated CD14+ 
cells in the presence or absence of p38 inhibitor (p38i) SB203580 (10μM). 
(A,B,C,E) Means+SD of CD73 mfi values from triplicate cultures are shown 
*p<0.05, **p<0.01, ***p<0.001.  
Figure 4. pSTAT3-mediated enhancement of CD73 induction and the 
function of CD73-expressing CD14+ cells. (A) Means+SD of pSTAT3 or isotype 
mfi values are shown from triplicate CD14+ cell samples at different times after 
sPE-treatment. (B) CD73 expression on CD14+ cells 48h after treatment with sPE 
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in the presence or absence of pSTAT3-inhibitor (STAT3i) Cpd188 (10μM). 
Means+SD of CD73 mfi from triplicate samples are shown. (C) pSTAT3 (left 
panel) or pSTAT1 (right panel) or isotype control mfi values are shown 30 min 
after treatment with sPE in the presence or absence of Cpd188 (STAT3i) as 
described above. Means+SD of triplicates. (D) CD14+ healthy donor cells were 
treated with sPE or NECA (250ng/ml) in the presence or absence of 10ng/ml IL-
6. Mfi of CD73 expression 48h later is shown as mean+SD of triplicate samples.  
(E) CD14+ cells were treated with sPE overnight. LPS-induced TNFα production 
was measured by intracellular cytokine staining in the presence or absence of 
AMP (200μM) or adenosine receptor A2A- and A2B-inhibitors (A2Ri; 200nM 
each), as indicated under the graph. Means+SD of the mfi of TNFα from triplicate 
samples are shown. *p<0.05, **p<0.01, ***p<0.001.  
Figure 5. The mechanism of CD73 induction on CD14+ cells. This cartoon 
summarizes the results of CD73-induction by adenosine, forskolin and PGE2, the 
inhibition of induction (dotted lines) by (1) PGE2 receptor inhibitors, (2) 
adenosine receptor inhibitors, (3) a PKA-inhibitor and (4) a p38-inhibitor. 
Negative regulation by pSTAT3 was demonstrated by a STAT3-inhibitor (5).  
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Table 1.  Details of PE donor MPM patients 
 
* Not otherwise specified 
** Pemetrexed and Cisplatin, 4 cycles 
 
 
Patients Age Gender Pathology PE Collection 
(time post 
diagnosis) 
Treatment history 
(time before PE 
collection) 
PE4 81 M Epithelioid 12 months Palliative RT (3 weeks pre-
collection) 
PE5 67 M Epithelioid 8 months None 
PE6 63 F NOS* 3 months None 
PE7 66 M Epithelioid 4 years 5 
months 
Pleurectomy (4 years 3 
months pre-collection). 
Pem/Cis** (11 months 
pre-collection) 
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Methods for Supplementary Data 
Human Cytokine Array 
Cytokine Array Kit (ARY005B) from R&D Systems was used to simultaneously detect the relative levels of 
36 different cytokines and chemokines in sPE and plasma, according to instructions. Pixel density was 
determined using Image-J software. Means of duplicate samples were calculated from average pixel 
density values minus negative control values. 
 
Mesothelioma cell proliferation following NECA treatment 
Cells of the primary mesothelioma line 15 (established by us, refs 17,18 in main paper) were plated into a 
96 well flat bottomed tray at 5x103cells/well in the presence of increasing concentrations of NECA as 
indicated on the figure. After 24h, the cells were labeled with 0.5 μCi 3H-thymidine overnight. The cells 
were harvested onto a filtermat and counted in a β-counter (Wallace, Perkin-Elmer).  
 
sPE treatment of monocytes and flow cytometry 
CD14+ cells were isolated from freshly prepared PBMC by positive isolation (StemCell Technologies). 
CD14+ cells were incubated for 48h in the presence or absence of 12.5% sPE. Cell surface labeling was 
carried out on ice for 30min using antibodies specific for CD3, CD14, CD16, CD86, HLA-DR, PDL-1, CD1c, 
CD62L, CD163 and CD73 (Affymetrix) and (BD-Biosciences).  A FACSVerse cytometer (BD-Biosciences) 
was used for cell phenotyping, and FACSDiva software for data analysis. 
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Figure S1. CD73 is upregulated on CD14+ cells by MPM PE. Means+SD of CD73 or isotype mean 
fluorescence intensity (mfi) from triplicate samples are shown following  48h treatment with (A) Nil, or 
50% of 75% sPE pooled from three donors, or (B) with nil and sPE from a further 6 individual donors. The 
Mix from samples 4-7 represents the pooled sPE from donors as listed in Table 1 of the main paper, and 
used in all experiments. sPE9 represents a sample from a patient with sarcomatoid subtype of 
mesothelioma. 
 
 
 
Figure S2 
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Figure S2. Phenotypic changes due to sPE-treatment on monocytes. (A) Marker expression on sPE -
treated or untreated (Nil) CD14+ cells.  (B) Marker expression on sPE-treated CD73+ vs. CD73- cells.  
Means+SD of antigen expression (as mean fluorescence intensity, mfi ) from triplicate samples are 
shown. Significant differences are shown as  **p<0.01 and ***p<0.001. 
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Figure S3. Cytokine array results from two PE, two MPM plasma and two healthy donor plasma samples. 
Means of duplicate readings of pixel densities for each cytokine shown are expressed as relative pixel 
densities, after background deduction, determined with Image J software. 
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Figure S4. NECA enhances mesothelioma cell proliferation (48h assay). Means+SD of 3H-thymidine 
uptake (cpm) by mesothelioma cells from 14 replicates per treatment group are shown. Significant 
differences are shown as  **p<0.01. 
 
